You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

453 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
exemestane
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
tamoxifen
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Drug
Other Name(s): Verzenio®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Cette plateforme contient des outils et des ressources pour les prestataires de soins primaires, les colposcopistes et d’autres professionnels de la...
Dans tout l’Ontario, les centres de cancérologie, les hôpitaux et les cliniques proposent une vaste gamme de services de dépistage, de diagnostic et...
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Updated
Mar 2025
Guidelines and Advice
Status: In-Review
ID: 19-4
Dec 1969
Guidelines and Advice
Status: In-Review
ID: GL END 3-23
Version: N/A
Oct 2021
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015

Pages